13.02.18: Not intended for U.S. and UK Media

Bayer receives first approval for Eylea® in ChinaEylea is the first anti-VEGF drug approved in China for the treatment of visual impairment due to diabetic macular edema in patients with DMEmehr ...

Source: Bayer IR Newsfeed: Events - February 13, 2018 Category: Pharmaceuticals Source Type: news